Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New portable MRI could spot fatty liver in minutes

NCT ID NCT05986916

Diagnosis Sponsor: University of California, San Diego Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This study is testing a new portable device called LiverScope that uses MRI-like technology to measure fat in the liver. Researchers will compare it to standard MRI and FibroScan in 50 adults with known or suspected non-alcoholic fatty liver disease (NAFLD). Participants undergo a one-time visit with scans and a blood draw. The goal is to see if LiverScope can reliably diagnose liver fat without needing a full hospital MRI.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
LiverScope® exam (portable MRI device)
What this could lead to
If successful, this could provide a simpler, more accessible way to diagnose and monitor fatty liver disease without needing large hospital MRI machines.
What could go wrong
This is a small, early-stage study (50 participants) focused on comparing measurements, not on treatment. The device is not yet approved for clinical use, and results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 50 people

The number the study aims to enrol. It can still change while the study runs.

Started

Aug 2023

Expected to finish

Nov 2025

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Adults with clinically known or suspected liver disease.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age:18 years or older * Known or clinically suspected NAFLD * Weight less than 350 lbs (safety limit of MR scanner table) * Able to lie on LiverScope® diagnostic table for about 15 min * Able to hold breath repeatedly for about 20 s during MR and LiverScope® exams * Willing and able to undergo all study procedures Exclusion Criteria: * VA patient only; not a UCSD patient * UCSD or Livivos study personnel * MR contraindication(s) * Potential participant states that she knows that she is pregnant, thinks she may be pregnant or states she is trying to become pregnant\* * Known chronic liver disease other than NAFLD

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NAFLD are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

metabolic dysfunction-associated steatotic liver disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NAFLD Nonalcoholic fatty liver

Contacts and locations

Locations

  • University of California San Diego

    La Jolla, California, 92037, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.